Abstract
AbstractThis study investigated a candidate vaccine effect against maternal Trypanosoma cruzi (Tc) infection and improved pregnancy outcomes. For this, TcG2 and TcG4 were cloned in a nanoplasmid optimized for delivery, antigen expression, and regulatory compliance (nano2/4 vaccine). Female C57BL/6 mice were immunized with nano2/4, infected (Tc SylvioX10), and mated 7-days post-infection to enable fetal development during the maternal acute parasitemia phase. Females were euthanized at E12–E17 (gestation) days. Splenic and placental T-cell responses were monitored by flow cytometry. Maternal and placental/fetal tissues were examined for parasites by qPCR and inflammatory infiltrate by histology. Controls included age/immunization-matched non-pregnant females. Nano2/4 exhibited no toxicity and elicited protective IgG2a/IgG1 response in mice. Nano2/4 signaled a splenic expansion of functionally active CD4+ effector/effector memory (Tem) and central memory (Tcm) cells in pregnant mice. Upon challenge infection, nano2/4 increased the splenic CD4+ and CD8+T cells in all mice and increased the proliferation of CD4+Tem, CD4+Tcm, and CD8+Tcm subsets producing IFNγ and cytolytic molecules (PRF1, GZB) in pregnant mice. A balanced serum cytokines/chemokines response and placental immune characteristics indicated that pregnancy prevented the overwhelming damaging immune response in mice. Importantly, pregnancy itself resulted in a significant reduction of parasites in maternal and fetal tissues. Nano2/4 was effective in arresting the Tc-induced tissue inflammatory infiltrate, necrosis, and fibrosis in maternal and placental tissues and improving maternal fertility, placental efficiency, and fetal survival. In conclusion, we show that maternal nano2/4 vaccination is beneficial in controlling the adverse effects of Tc infection on maternal health, fetal survival, and pregnancy outcomes.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology
Reference62 articles.
1. Bonney, K. M., Luthringer, D. J., Kim, S. A., Garg, N. J. & Engman, D. M. Pathology and pathogenesis of Chagas heart disease. Ann. Rev. Pathol. Mech. Dis. 14, 421–447 (2020).
2. Lidani, K. C. F. et al. Chagas disease: from discovery to a worldwide health problem. Front. Public Health 7, 166 (2019).
3. World Health Organization. Chagas Disease (also known as American trypanosomiasis): Key Facts. https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis). (UNDP/World Bank/WHO, Geneva, Switzerland, 2022).
4. Rios, L., Campos, E. E., Menon, R., Zago, M. P. & Garg, N. J. Epidemiology and pathogenesis of maternal-fetal transmission of Trypanosoma cruzi and a case for vaccine development against congenital Chagas disease. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 165591 (2020).
5. Klein, M. D. et al. Risk factors for vertical transmission of Chagas disease: a systematic review and meta-analysis. Int. J. Infect. Dis. 105, 357–373 (2021).